Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
Brentuximab injection is used to treat Hodgkin lymphoma, systemic anaplastic large cell lymphoma (sALCL), and primary cutaneous anaplastic large cell lymphoma (pcALCL), which are blood cancers. It is given to patients who have received a bone marrow (autologous stem cell) transplant or other cancer treatments that did not work well.
Brentuximab injection is also used together with other cancer medicines (eg, doxorubicin, vinblastine, dacarbazine) to treat a previously untreated stage III or IV classical Hodgkin lymphoma.
Brentuximab injection is also used together with other medicines (eg, cyclophosphamide, doxorubicin, prednisone) to treat patients with previously untreated sALCL or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL.
Brentuximab interferes with the growth of cancer cells, which are then destroyed by the body.
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: May 01, 2023
Copyright: © Merative US L.P. 1973, 2023. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.